[Mesenchymal stem cells as an antitumor therapy tool]

Area of Science:

• Oncology
• Regenerative Medicine
• Molecular Biology

Background:

• Developing low-toxicity, high-selectivity antitumor agents is crucial for cancer gene therapy.
• Mesenchymal stem cells (MSCs) exhibit natural tumor-homing properties, making them ideal vectors for targeted gene delivery.
• Current therapeutic genes for MSC delivery include enzymes, cytokines, and apoptosis-inducing factors.

Purpose of the Study:

• To evaluate the potential of mesenchymal stem cells as vehicles for targeted cancer gene therapy.
• To assess the efficacy of MSC-mediated delivery of therapeutic genes in preclinical tumor models.

Main Methods:

• Utilizing mesenchymal stem cells for targeted delivery of genes encoding therapeutic proteins (e.g., enzymes, cytokines, TRAIL).
• Employing experimental models of various tumor etiologies, including brain and lung metastases in animals.

Main Results:

• Mesenchymal stem cells successfully delivered therapeutic genes to tumor sites in experimental models.
• Significant antitumor effects were observed in animals treated with MSC-delivered therapeutic genes.
• MSC-mediated gene therapy demonstrated efficacy against tumors with different origins and metastatic spread.

Conclusions:

• Mesenchymal stem cells are effective vehicles for targeted delivery of therapeutic genes in preclinical cancer models.
• MSC-based gene therapy holds significant potential for treating various cancers, including metastatic disease.
• Further technical advancements are necessary to translate this promising therapeutic strategy into clinical practice.